Coronary interventions

Neointimal hyperplasia of ultra-thin stents with microcrystalline sirolimus or durable polymer everolimus-eluting stents: 6- and 24-month results of the DESSOLVE III OCT study

EuroIntervention 2021;16:1187-1194. DOI: 10.4244/EIJ-D-18-01201

Krzysztof Milewski
Krzysztof Milewski1,2, MD, PhD; Kuniaki Takahashi3, MD; Taku Asano3, MD; Yuki Katagiri3, MD; Mariusz Hochul1, MD; Piotr P. Buszman1, MD, PhD; Mariusz Tomaniak4,5, MD; Bogdan Gorycki1, MD, PhD; Aleksander Zurakowski1, MD, PhD; Adam Janas1, MD, PhD; Adam Mlodziankowski1, MD; Mateusz Kachel1, MD; Joanna J. Wykrzykowska3, MD, PhD; William Wijns6, MD, PhD; Robbert J. de Winter3, MD, PhD; Pawel E. Buszman1,7, MD, PhD; Yoshinobu Onuma5,8, MD, PhD; Patrick W. Serruys9, MD, PhD
1. Center for Cardiovascular Research and Development, American Heart of Poland, Katowice, Ustron, Poland; 2. The Jerzy Kukuczka Academy of Physical Education, Faculty of Physiotherapy, Katowice, Poland; 3. Department of Cardiology, Academic Medical Center, Amsterdam, the Netherlands; 4. Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands; 5. First Department of Cardiology, Medical University of Warsaw, Warsaw, Poland; 6. The Lambe Institute for Translational Medicine and Curam, Saolta University Healthcare Group, National University of Ireland Galway, Galway, Ireland; 7. Medical University of Silesia in Katowice, Katowice, Poland; 8. Cardialysis, Rotterdam, the Netherlands; 9. Department of Cardiology, National University of Ireland Galway (NUIG), Galway, Ireland

Aims: The DESSOLVE III OCT substudy aimed to compare serially neointimal hyperplasia volume obstruction (%VO) between the thin-strut MiStent with early polymer elimination and nine-month sustained drug release from microcrystalline sirolimus and the durable polymer-coated everolimus-eluting XIENCE stent at six and 24 months after implantation.

Methods and results: The efficacy endpoint was %VO, calculated as abluminal neointimal volume/stent volume. Thirty-six patients (MiStent 16 patients, 16 lesions; XIENCE 20 patients, 22 lesions) underwent serial OCT evaluation at both six and 24 months. At six months, mean abluminal %VO was significantly lower in the MiStent group than in the XIENCE group (14.54±3.70% vs 19.11±6.70%; p=0.011), whereas the difference in %VO between the two groups decreased at 24 months (20.88±5.72% vs 23.50±7.33%; p=0.24). There was no significant difference in percentage malapposed struts and percentage uncovered struts between the two groups at both time points.

Conclusions: In the serial comparative OCT analysis of the MiStent versus the XIENCE, the MiStent showed a more favourable efficacy for preventing neointimal formation with comparable strut tissue coverage, as compared with the XIENCE at six months, but this difference in %VO decreased at 24 months so that the difference in neointima at 24 months was no longer significant.

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

drug-eluting stentoptical coherence tomographyquantitative coronary angiography
Coronary interventionsStents and scaffolds
Read next article
Prognostic significance of thermodilution-derived coronary flow capacity in patients with deferred revascularisation

Latest news